Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines

Area of Science:

• Virology
• Immunology
• Pediatrics

Background:

• Enterovirus 71 (EV71) is a significant pathogen within the Picornaviridae family, responsible for Hand, Foot, and Mouth Disease (HFMD) in young children.
• EV71 infections can lead to severe neurological complications, including encephalitis, posing a substantial public health threat.
• The absence of approved vaccines and antiviral treatments necessitates urgent development of countermeasures.

Purpose of the Study:

• To review recent progress in the development of anti-therapeutics and vaccines for Enterovirus 71.
• To provide an overview of emerging strategies for preventing and treating EV71 infections.

Main Methods:

• Review of scientific literature on EV71 vaccine and therapeutic development.
• Analysis of different vaccine platforms, including inactivated and baculovirus-expressed vaccines.
• Evaluation of therapeutic approaches such as intravenous immunoglobulin (IVIg) and monoclonal antibody therapy.

Main Results:

• Several vaccine candidates, including inactivated and baculovirus-expressed vaccines, are under investigation.
• Human intravenous immunoglobulin (IVIg) and monoclonal antibody therapies show promise for prevention and treatment.
• Progress has been made in developing diverse strategies to combat EV71.

Conclusions:

• The development of effective vaccines and antiviral therapies for EV71 is crucial for protecting vulnerable populations, particularly young children.
• Multiple promising avenues, including various vaccine types and immunotherapies, are being explored.
• Continued research and development are essential to address the threat posed by EV71.